[Helicobacter pylori infection: extragastric effects and diseases (a critical analysis)].
The article presents a critical analysis of the attempts of other authors to propagate the significance of Helicobacter pylori (HP) infection in the origin and development of a range of extragastric diseases and syndromes. From the position of evidence-based medicine, the author of the article discusses the possibility of HP participation in the development of such diseases as cholelithiasis, primary sclerosing cholangitis, pancreobiliary cancer, hepatic encephalopathy in hepatic cirrhosis, pancreatic diseases, inflammatory bowel diseases, atherosclerosis, coronary heart disease, allergic diseases etc. The author concludes that the attempts to associate the development of these diseases with HP infection are in general unfounded and not evidence-based. The author also adduces his own data on the role of the mucose microflora (other than HP) in the pathogenesis of duodenal ulcer relapses, and the effects of differentiated antimicrobial therapy, which are not less prominent than those of HP eradication.
Tsimmerman
Ia S
IaS
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004066:Digestive System Diseases / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control; D005753:Gastric Mucosa / Q000382:microbiology; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control; D012307:Risk Factors
D000900:Anti-Bacterial Agents